Many Who Start Antipsychotics Discontinue Treatment
More than a third of people with Parkinson’s disease who are prescribed antipsychotics stop treatment within six months of…
Articles by Marisa Wexler, MS
Jaw Exercises, Oral Hygiene Advice Aids Life Quality in Later Parkinson’s
A program of jaw-related exercises, coupled with individualized advice for oral hygiene, can improve quality of life as it relates…
Low Levels of Some Fatty Acids Found in Parkinson’s Patients
People with Parkinson’s disease have lower-than-normal levels of certain fatty acids in their blood, which is not explained by…
MJFF Offering Online Guide for Patients Considering DBS
The Michael J. Fox Foundation (MJFF) has released a new guide that aims to help people with Parkinson’s disease…
Targeting Mitochondrial DNA May Be Therapeutic Strategy
In Parkinson’s disease, DNA that leaks out of mitochondria — small organelles that generate energy — leads to cell death…
FDA Rejects Verily’s Smartwatch for Parkinson’s Assessment
The U.S. Food and Drug Administration (FDA) has rejected an application from Verily Life Sciences that sought to add…
Phase 1 Trials of Bayer’s Cell and Gene Therapies Enrolling Patients
The first patient has been dosed in a still-recruiting Phase 1 clinical trial testing DA01, an investigational cell therapy for…
Antipsychotic Use by Newly Diagnosed Patients Drops After FDA Warnings
The use of antipsychotics by people with early Parkinson’s disease (PD) has fallen substantially since the U.S. Food and…
FDA Approves Advanced DBS System Allowing More Personalized Care
The U.S. Food and Drug Administration (FDA) has approved Medtronic‘s SenSight Directional Lead System, which offers both sensing and directional…
Data Support Long-term Efficacy of Nuplazid for Psychosis
Treatment with Nuplazid (pimavanserin) can ease symptoms of Parkinson’s disease psychosis (PDP) for up to 10 weeks, and…